Evaluation of the efficacy of injectable chondroitin sulfate for knee osteoarthritis in real clinical practice
https://doi.org/10.14412/1996-7012-2019-3-130-134
Abstract
Objective: to carry out a statistical analysis of clinical material obtained in an open-label observational study of the efficacy and safety of injectable chondroitin sulfate (ICS) in real clinical practice.
Patients and methods. A total of 170patients with knee osteoarthritis (OA) (78.8% females; mean age, 60.5+8.3 years) who experienced severe pain and needed to regularly take non-steroidal antiinflammatory drugs (NSAIDs) were examined. All the patients received a cycle of therapy with ICS (25 intramuscular injections every other day). The treatment results were assessed by the changes of pain intensity at rest and during movement and general health status (a 100 mm visual analogue scale) at 2 months after therapy initiation. The dynamics of NSAID use, therapy tolerance, and patient assessment of treatment outcomes were also taken into account.
Results and discussion. There were decreases in the median severity of pain at rest from 40.0 [20.0; 70.0] to 10.0 [0.0; 20.0] mm, in pain during movement from 65.0 [58.0; 80.0] to 20.0 [10.0; 30.0] mm, and in overall health status assessment from 60.0 [50.0; 70.0] to 20.0 [10.0; 40.0] mm (p < 0.001). It might be possible to discontinue NSAIDs or to reduce their dose/frequency in 87.9% of patients. 83.3% of patients rated their treatment results as good and excellent. No serious adverse reactions were observed.
Such a beneficial effect of therapy should be taken with some caution, since it has been obtained during an open-label uncontrolled observational study. Although the injection of this type of pharmacological agents is practically not used in Western countries; Russia has meaningful and generally positive experience with injectable slow-acting symptom-modifying drugs (SMDs), including CS. The advantages of this procedure are an enhanced bioavailability of SMDs, an accelerated onset of an analgesic effect, and higher patient adherence to therapy. Conclusion. The findings showed the good efficacy and tolerance of ICS in patients with knee OA in real clinical practice.
About the Authors
E. Yu. PogozhevaRussian Federation
34A, Kashirskoe Shosse, Moscow 115522.
A. E. Karateev
Russian Federation
Andrey Evgenyevich Karateev.
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 446 p.
2. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi:10.1016/j.semarthrit.2015.11.010 Epub 2015 Dec 2
3. Lila AM, Gromova OA, Torshin IYu, et al. Molecular effects of chondroguard in osteoarthritis and herniated discs. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(3):88—97. (In Russ.). doi: 10.14412/2074-2711-2017-3-88-97
4. Honvo G, Bruyere O, Geerinck A, et al. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Adv Ther. 2019 May;36(5):1085-1099. doi: 10.1007/s12325-019-00921-w. Epub 2019 Mar 16.
5. Knapik JJ, Pope R, Hoedebecke SS, et al. Effects of Oral Chondroitin Sulfate on Osteoarthritis-Related Pain and Joint Structural Changes: Systematic Review and Meta-Analysis. J Spec Oper Med. Spring 2019; 19(1):113-124.
6. Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1: S28-31. doi: 10.1016/jjoca.2010.02.016. Epub 2010 Apr 27.
7. Nasonova VA, Alekseeva LI, Arkhangel'skaya GS, et al. The results of the multicenter clinical trial of Structum in Russia. Terapevticheskii arkhiv. 2001;(11):84—7. (In Russ.).
8. Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther. 2014 Jun;142(3):362-74. doi: 10.1016/j.pharmthera.2014.01.002. Epub 2014 Jan 21.
9. Rainsford KD. Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique. JPharm Pharmacol. 2009 Oct;61(10):1263-70. doi: 10.1211/jpp/61.10.0001.
10. Shang Q, Yin Y, Zhu L, et al. Degradation of chondroitin sulfate by the gut microbiota of Chinese individuals. Int J Biol Macromol. 2016 May;86:112-8. doi: 10.1016/j.ijbiomac.2016.01.055. Epub 2016 Jan 19.du
11. Zotkin EG, Kharitonova TV, Shkireeva SYu. Possibilities of clinical application of chondroitin sulfate for parenteral administration in patients with osteoarthritis in geriatric practice. Uspekhigerontologii. 2014;27(2):366-75. (In Russ.).
12. Karateev AE, Lila AM. Russian experience with injectable chondroitin sulfate and glucosamine sulfate: a review of clinical trials. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(1):33-40. doi: 10.14412/1996-7012-2018-1-33-40
13. Belousov DYu. Post-registration clinical trials. Kachestvennaya klinicheskaya praktika. 2017;(1):20-3. (In Russ.).
14. Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015 Jan 28;1: CD005614. doi: 10.1002/14651858.CD005614.pub2.
15. Reichelt A, Forster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung. 1994 Jan;44(1):75-80.
16. Pavelka K, Gatterova J, Gollerova V, et al. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage. 2000 Sep; 8(5):335-42.
17. Shostak NA. Osteoarthritis: topical issues of diagnosis and treatment. Russkii meditsinskii zhurnal. 2014;(4):278-81. (In Russ.).
18. Danilov AB. Antinociceptive effect of chondroprotectors — myth or reality? Manage pain. 2018;(1):8-13. (In Russ.).
19. Persanova LV, Khlyabich KG. MUCOSAT (mucosatum). An effective treatment for degenerative and inflammatory diseases of the musculoskeletal system. Vestnik sluzhby kroviRossii. 2011;(1):43-4. (In Russ.).
20. Dydykina IS, Kovalenko PS, Kovalenko AA. The completion of the modern arsenal of the treatment of osteoarthritis. Domestic product chondroitin sulfate: focus on the safety of its use. Farmateka. 2018;(2):12-9. (In Russ.).
Review
For citations:
Pogozheva EY, Karateev AE. Evaluation of the efficacy of injectable chondroitin sulfate for knee osteoarthritis in real clinical practice. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(3):130-134. (In Russ.) https://doi.org/10.14412/1996-7012-2019-3-130-134